Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05819619 · ClinicalTrials.gov registry record · Early Phase 1
Prophylactic Analgesic and Antiemetic Regimen for Medical Abortion < 70 Days
A Early Phase 1 study, sponsored by Hackensack Meridian Health.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT05819619 is a Early Phase 1 study that was terminated before completion, run by Hackensack Meridian Health. The registered enrollment target is 8 participants.
The verdict
NCT05819619, a Early Phase 1 study, was terminated before completion, sponsored by Hackensack Meridian Health.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Randomized trial which will aim to evaluate whether prophylactic use of ondansetron and ibuprofen will decrease side effects associated with medical abortion and increase patient satisfaction.
Interventions
- DRUG Prophylactic use of ibuprofen and ondansetron post misoprostol administration
- DRUG Use of ibuprofen and ondansetron at symptom onset post misoprostol administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-07-20 |
| Est. Completion | 2024-04-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05819619
The ClinicalTrials.gov registry entry for NCT05819619 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prophylactic use of ibuprofen and ondansetron post misoprostol administration is the first listed.
NCT05819619 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05819619 about?
NCT05819619 is a clinical study titled "Prophylactic Analgesic and Antiemetic Regimen for Medical Abortion < 70 Days". Randomized trial which will aim to evaluate whether prophylactic use of ondansetron and ibuprofen will decrease side effects associated with medical abortion and increase patient satisfaction.
What is the current status of trial NCT05819619?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2023-07-20. Estimated completion is 2024-04-11.
What interventions are being tested in trial NCT05819619?
The interventions under investigation include: Prophylactic use of ibuprofen and ondansetron post misoprostol administration (DRUG), Use of ibuprofen and ondansetron at symptom onset post misoprostol administration (DRUG).
Who is sponsoring clinical trial NCT05819619?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.